Ewing’s Sarcoma Market

Market Overview:

The 7 major ewing’s sarcoma markets reached a value of US$ 47.8 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 74.5 Million by 2034, exhibiting a growth rate (CAGR) of 4.1% during 2024-2034.

The Ewing’s sarcoma market has been comprehensively analyzed in IMARC's new report titled "Ewing’s Sarcoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Ewing's sarcoma is a rare type of oncological disease that affects primitive nerve tissue of bones or soft tissues surrounding the bones. It most commonly occurs in the long bones of the arms and legs but can also develop in the soft tissues of the limbs, chest, or abdomen. Individuals suffering from this condition may experience pain, tenderness or swelling near the affected area, bone pain, limping, extreme tiredness, fever with no known cause, unexplained weight loss, etc. The other infrequent symptoms include palpable soft-tissue mass, paralysis, loss of bladder control, and bone fractures. The diagnosis of Ewing's sarcoma is mainly made by reviewing the patient's underlying indications, medical history, and physical examination. Numerous other studies, like magnetic resonance imaging (MRI), computed tomography (CT) scans, positron emission tomography (PET) scans, etc., are also utilized to look for signs of bone damage. The healthcare provider may further perform a biopsy, which involves the removal of tiny samples of the affected region to examine it under a microscope and validate a diagnosis.

The increasing cases of genetic abnormalities that lead to the disruption of normal tissues and the formation of unhealthy cells throughout the body are primarily driving the Ewing's sarcoma market. In addition to this, the widespread adoption of radical chemotherapy, which aims at complete irradiation of tumors, is also bolstering the market growth. Furthermore, the escalating demand for antisense oligodeoxynucleotide therapy to treat locally advanced disease conditions by down-regulating the expression of the oncogenic cellular RNA associated with the development of Ewing's sarcoma is acting as another significant growth-inducing factor. Additionally, the inflating utilization of proton beam radiation technique, which delivers an effective dose and controls damage to healthy tissues surrounding the cancerous cells, is further creating a positive outlook for the market. Apart from this, the emerging popularity of autologous stem cell transplantation as a viable treatment option owing to reduced metastasis and improved disease-free survival of patients, is expected to drive the Ewing's sarcoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Ewing’s sarcoma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Ewing’s sarcoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Ewing’s sarcoma market in any manner.

Recent Developments:

• In November 2023, Salarius Pharmaceuticals, Inc. disclosed that it attended a Type B End-of-Phase 2 (EOP2) conference with the US Food and Drug Administration (FDA) to get guidance on the seclidemstat development program for the treatment of Ewing sarcoma. The Company has received the final meeting minutes and is updating the current clinical trial protocol to incorporate the guidance agreed upon with the FDA at the EOP2 conference.
• In September 2023, Carrick Therapeutics reported that the FDA has approved Investigational New Drug application for CT7439, a new cyclin dependent kinase 12/13 (CDK12/13) inhibitor. The Phase 1 clinical study will begin in the first half of 2024, including patients with advanced solid tumors such as Ewing's sarcoma.

Key Highlights:

• In the United States, the annual incidence of Ewing sarcoma is about one case per million people.
• The incidence from infancy to age 20 is 2.9 incidences per million people.
• Whites are at least nine times more likely than Blacks to develop these malignancies.
• The incidence of Ewing sarcoma in females is 2.6 cases per million population, compared to 3.3 occurrences per million population in males.
• These tumors are more common in late adolescence.

Drugs:

Lurbinectedin, also called PM01183, or commercially where approved as Zepzelca, is used for the treatment of Ewing's sarcoma. Lurbinectedin suppresses active transcription of protein-coding genes by binding to promoters and irreversibly delaying elongating RNA polymerase II on the DNA template, causing double-stranded DNA breaks and death.

Vigil is a personalized immunotherapy platform that combines a unique bi-shRNA DNA plasmid with the patient's tumor tissue to achieve immunological anticancer action. The Trifecta of systemic action entails inhibiting tumor suppressor cytokines TGFβ1 and TGFβ2, increasing GMCSF expression to improve local immune function, and presenting clonal neoantigen epitopes using autologous cancer tissue. Vigil uses the patient's tumor as an antigen source to trigger an immune response tailored to their specific clonal tumor neoantigens.

Seclidemstat (SP-2577) is a differentiated inhibitor of LSD1, a well-established target for both hematological and solid malignancies. SP-2577 inhibits LSD1's enzymatic activity and scaffolding role.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Ewing’s sarcoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Ewing’s sarcoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Ewing’s sarcoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Ewing’s sarcoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the Ewing’s sarcoma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the Ewing’s sarcoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of Ewing’s sarcoma across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Ewing’s sarcoma by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Ewing’s sarcoma by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with Ewing’s sarcoma across the seven major markets?
• What is the size of the Ewing’s sarcoma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of Ewing’s sarcoma?
• What will be the growth rate of patients across the seven major markets?
   

Ewing’s Sarcoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Ewing’s sarcoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Ewing’s sarcoma market?
• What are the key regulatory events related to the Ewing’s sarcoma market?
• What is the structure of clinical trial landscape by status related to the Ewing’s sarcoma market?
• What is the structure of clinical trial landscape by phase related to the Ewing’s sarcoma market?
• What is the structure of clinical trial landscape by route of administration related to the Ewing’s sarcoma market?